Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery
Kai-Wen Ho,Yen-Ling Liu,Tzu-Yi Liao,En-Shuo Liu,Tian-Lu Cheng
DOI: https://doi.org/10.2147/ijn.s479270
IF: 7.033
2024-10-01
International Journal of Nanomedicine
Abstract:Kai-Wen Ho, 1, 2 Yen-Ling Liu, 2, 3 Tzu-Yi Liao, 2, 3 En-Shuo Liu, 2, 3 Tian-Lu Cheng 1– 3 1 Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; 2 Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan; 3 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan Correspondence: Tian-Lu Cheng, Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, No. 100 Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan, Tel +886 7 3121101 2697, Fax +886 7 3227508, Email Polyethylene glycol (PEG)-modified nanoparticles (NPs) often struggle with reduced effectiveness against metastasis and liquid tumors due to limited tumor cell uptake and therapeutic efficacy. To address this, actively targeted liposomes with enhanced tumor selectivity and internalization are being developed to improve uptake and treatment outcomes. Using bi-functional proteins to functionalize PEGylated NPs and enhance targeted drug delivery through non-covalent attachment methods has emerged as a promising approach. Among these, the one-step and two-step targeting strategies stand out for their simplicity, efficiency, and versatility. The one-step strategy integrates streptavidin-tagged antibodies or bispecific antibodies (bsAbs: PEG/DIG × marker) directly into PEGylated NPs. This method uses the natural interactions between antibodies and PEG for stable, specific binding, allowing the modification of biotin/Fc-binding molecules like protein A, G, or anti-Fc peptide. Simply mixing bsAbs with PEGylated NPs improves tumor targeting and internalization. The two-step strategy involves first accumulating bsAbs (PEG/biotin × tumor marker) on the tumor cell surface, triggering an initial attack via antibody-dependent and complement-dependent cytotoxicity. These bsAbs then capture PEGylated NPs, initiating a second wave of internalization and cytotoxicity. Both strategies aim to enhance the targeting capabilities of PEGylated NPs by enabling specific recognition and binding to disease-specific markers or receptors. This review provides potential pathways for accelerating clinical translation in the development of targeted nanomedicine. Keywords: PEGylated nanoparticle, monoclonal antibody, antibody-containing nanodrugs, functionalization, targeted cancer therapy Polyethylene glycol (PEG)-based nanoparticles (NPs) are diverse and promising drug delivery vehicles. PEG is water-soluble, non-toxic, and used as an excipient in medication formulations to improve pharmacokinetics, biodistribution, solubility, and stability, reducing side effects. 1–3 PEG polymers coupled to a lipid anchor inhibit the reticuloendothelial system (RES). The PEGylated NPs escape from the RES system and are stable within PEGylated liposomes, extending their half-life and enhancing therapeutic efficacy. 4–8 The use of nanotechnology to develop these systems has been well-established over the past decade, both in pharmaceutical research and the clinical setting. For instance, Doxil and Caelyx, which are PEGylated liposomal doxorubicin (PLD) 9–11 have been utilized in treating AIDS-related Kaposi's sarcoma and solid cancers. 10 The pharmacokinetic profile of Doxil at 50 mg/m2 in humans shows a 300-fold increase in the area under the curve (AUC) compared to the free drug. 10,12 Metastatic pancreatic cancer patients can receive Onivyde, a PEGylated liposomal irinotecan. 13,14 After administering Onivyde 60–180 mg/m 2 to cancer patients, the overall AUC increased by 46.2 times compared to nonliposomal irinotecan. 15,16 Tumor accumulation of PEGylated NPs can boost treatment efficiency due to the enhanced permeability and retention (EPR) effect. 17–19 Although non-targeted PEGylated NPs exhibit improved pharmacokinetics by evading the RES, EPR effects-lacking metastases and liquid tumors present difficulties. PEGylated NPs may internalize less in metastatic or hematopoietic cancers. PEGylated NPs had one-third of the intracellular absorption of non-PEGylated NPs. 20 PEGylated NPs are less effective against metastasis or liquid tumors because the EPR effect is weaker, reducing tumor cell uptake and therapeutic efficacy. Thus, actively targeted liposomes with tumor selectivity and internalization augmentation are needed to promote tumor uptake and therapeutic efficacy. The significance of active targeted PEGylated NP internalization lies in its pivotal role in optimizing drug delivery to solve hematologic malignancies, metastasis, and drug resistance. 21–25 Hematologic malignancies like leuke -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology